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Experimental section 
 
Filter retention assay 
The affinities of the aptamers used in this study to their target molecule thrombin were analyzed by filter 
retention. 10 pmol aptamer were radioactive 5´ phosphorylated by 20 U T4 Polynucleotide Kinase (New 
England BioLabs) in 70 mM Tris-HCl buffer pH 7.6 containing 10 mM MgCl2, 5 mM Dithiothreitol and 
300 µM γ-32P-ATP. γ-32P-ATP was purchased from PerkinElmer. Different Thrombin concentrations 
were incubated with 0.5 nM 32P-labeled aptamer 30 min at 37 °C in PBS pH 7.4 containing 1 mg/ml 
BSA, 1 mM CaCl2 and 1 mM MgCl2. Thrombin was purchased from Haematologic Technologies Inc. 
After incubation, the reactions were passed through 0.45 µm nitrocellulose membranes (Whatman) and 
washed 3 times with 200 µl PBS buffer containing 1 mM CaCl2 and 1 mM MgCl2. Bound aptamers were 
quantified with the Fujifilm FLA 3000 PhosphorImager. 
 
CD-spectroscopy  
CD spectra were recorded by a Jasco J-810 circular dichroism spectropolarimeter using a quartz cell with 
1 mm optical path length and a wavelength range from 230 to 320 nm at 1 nm bandwidth, 1 nm step size, 
and 0.5 s time per point. 50 µM final aptamer concentration in PBS pH 7.4 were heated to 95 °C for 1 
min and cooled to room temperature for 30 min. The CD spectra were obtained by taking the average of 
seven scans. 
 
Melting temperature 
The melting temperature (TM) was determined by a Perkin-Elmer UV/Vis Spectrometer Lambda 2S with 
a Peltier-controlled thermostatting PTP-1 system using a quartz cell with 1 cm optical path length. 
Absorbance of 10 µM final aptamer concentration in PBS pH 7.4 was measured at 295 nm as a function 
of temperature. Absorbance versus temperature curves from 25 to 90 °C with a heating rate of 0.5 °C/min 
were differentiated to determine TM values.  
 
Thrombin time 
The anticoagulant activity of aptamer variants was analyzed by a one-stage plasma-based thrombin-time 
(TT) assay using an Amelung KC10 A Coagulometer (Amelung, Lemgo, Germany). Human α-thrombin 
(CellSystems, Troisdorf, Germany) was diluted in assay buffer (1 ×PBS, pH 7.4, 3 mM MgCl2, 1 µg/µl 
BSA) to reach a final concentration of 10 NIH U/ml (75 nM). This thrombin solution was spiked with the 
aptamer variants to yield the indicated concentrations. After incubation of 75 µL-aliquots of this solution 
for 4 min at 37°C in measuring cuvettes, 75 µl of normal pooled human plasma (NPP) were added and 
the formation time of a fibrin clot, resulting from direct cleavage of plasma fibrinogen by thrombin, 
measured.  
 
Activated partial thromboplastin time 
Aptamer variants were added to NPP at indicated concentrations and samples introduced to activated 
partial thromboplastin time (aPTT) measurements. In clinical diagnostics, this plasma-based two-stage 
clotting assay is used to assess the overall coagulation potency in patient plasma or for the monitoring of 
anticoagulant therapies by e.g. thrombin-inhibiting drugs. Analysis was done using an automated BCS XP 
coagulation analyzer (Siemens Healthcare Diagnostics, Marburg, Germany). During the process, 50 µl of 
plasma samples were added to measuring cuvettes and 50 µl of Actin FS solution (Siemens) added. This 
reagent contains ellagic acid to activate the so-called contact phase of the plasmatic coagulation cascade. 
After incubation at 37°C for 3 min, to allow for Ca2+-dependent generation of thrombin and following 
clot formation, 50 µl of a CaCl2-solution (25 mM) were added and clotting times measured.  
 
Whole blood clotting assay (ROTEM®) 
Rotation thrombelastometry (ROTEM®) was used to assess the anticoagulant activity of aptamers and 
bivalirudin in whole blood. At this, a ROTEM® coagulation analyzer (TEM International, Munich, 
Germany) was used to measure the whole blood clotting time (CT). In brief, citrated whole blood was 
aliquoted and spiked with molecules to yield final concentrations of 1 µmol/L each. Subsequently, 320 µl 
of each sample and 20 µl of starting solution (0.1 M Hepes, pH 7.4; 0.2 M CaCl2) were added to fixed 
cuvettes, mixed, and clotting times (initial change of viscosity) automatically measured by the ROTEM® 
system. AD1-22 sequence: 5´-ACCACGGACTTTTTTTTTTTTTTTTCCAACCACAC-3´ 
 
Oligonucleotide synthesis and purification  
Oligonucleotide synthesis was carried out on an ExpediteTM Nucleic Acid Synthesis System Model 8909 
from Applied Biosystems in 200 nmol scale on 500 Å CPG supports with 1H-tetrazole as an activator for 
coupling reaction. The amidites P, O and Y were dissolved in dry dichloromethane and inserted into the 
growing oligonucleotide chain using an extended coupling time (15 min). In case of HD1-22 modified 
aptamers, the synthesis was carried out in 1000 nmol scale. Coupling efficiencies for monomers P, O and 
Y as well as the overall yield were shown in Table S1 based on the difference in absorbance of the 
dimethoxytrityl cation released. Cleavage from solid support and removal of nucleobase protecting 
groups was performed using standard conditions (32% aqueous ammonia for overnight at 55 ºC). The 
modified oligonucleotide aptamers were purified by DMT-off RP-HPLC program using Waters system 
600 in which the XBridge precolumn (10 × 10 mm, 5µm) was equipped with XBridge OST C18( 10 × 50 
mm, 2.5µm) Chromatography System. Elution was performed starting with an isocratic hold of buffer A 
for 2 min followed by a linear gradient to 70% buffer B in 17 min then linear gradient to 100% buffer B 
in 0.5 min and then 100% buffer A in 5.2 min at a flow rate of 2.5 ml /min at oven temperature 45°C 
(Buffer A: 0.05M triethylammonium acetate (pH 7.4); Buffer B: 75% MeCN/25% Buffer A). 
Precipitation was accomplished using pure acetone via addition of 100 µl double filtered water followed 
by aqueous sodium perchlorate (5 M, 15 µl) then pure acetone (1 ml). HD1 type modified ODNs were 
confirmed by MALDI-TOF analysis on a Ultraflex II TOF/TOF system from Bruker (a MALDI-LIFT 
system) with HPA-matrix (10 mg 3-hydroxypicolinic acid, in 50 mM ammoniumcitrate/70% acetonitril) 
matrix as shown in Table S1. The purity of the final TFOs was found to be over 95%, checked by ion-
exchange chromatography using La-Chrom system from Merck Hitachi on Dionex DNAPac Pa-100, 4 
×250 mm Analytical column using perchlorate buffer at pH 8 with 1 ml /min flow rate. 
 
NMR experiments 
The TINA-modified molecule, HD1 r8P, was dissolved in 0.5 mL mixture of H2O and D2O (9:1) with 10 
mM sodium phosphate buffer (pH 7.0) and 100 mM KCl. The concentration of the oligonucleotide was 
0.7 mM. NMR experiments were performed on a Varian UNITY 500 spectrometer at 25°C. A NOESY 
spectrum with a mixing time of 250 ms was acquired using the WATERGATE pulse sequence with 2048 
complex points in t2 and a spectral width of 10,000 Hz. A total of 512 t1 experiments, each with 120 scans 
and a dwell-time of 2.0 s between scans, were recorded using the States phase cycling scheme. 
 
 
Supporting Table S1 
   
Oligonucleotide Sequence Overall 
yield (%) 
P,O and Y 
coupling 
(%) 
Found 
m/z	   [M-
H]- 
Calc. m/z	  
[M-H]- 
HD1 r7P GGTTGGPGTGGTTGG  82 96 4887.0 4889.2 
HD1 r8P GGTTGGTPTGGTTGG  78 94 4862.0 4864.2 
HD1 r9P GGTTGGTGPGGTTGG  82 95 4885.9 4889.2 
HD1 r7O GGTTGGOGTGGTTGG  73 90 4888.9 4889.8 
HD1 r8O GGTTGGTOTGGTTGG  70 92 4864.5 4864.8 
HD1 r9O GGTTGGTGOGGTTGG  78 92 4895.9 4889.8 
HD1 r7O r8P GGTTGGOPTGGTTGG  78 97 (P) 
94 (O) 
5028.6 5028.0 
HD1 r7Y GGTTGGYGTGGTTGG  82 100 4881.4 4880.8 
HD1 r8Y GGTTGGTYTGGTTGG  81 99 4858.4 4855.8 
HD1 r9Y GGTTGGTGYGGTTGG  81 100 4881.8 4880.8 
HD1 i1P PGGTTGGTGTGGTTGG  78 - 5196.5 5193.4 
HD1 i3P GGPTTGGTGTGGTTGG  76 92 5193.9 5193.4 
HD1 i6P GGTTGPGTGTGGTTGG  78 95 5190.1 5193.4 
HD1 i8P GGTTGGPTGTGGTTGG  79 96 5197.4 5193.4 
HD1 i9P GGTTGGTPGTGGTTGG  79 97 5195.6 5193.4 
HD1 i12P GGTTGGTGTGGPTTGG  76 94 5196.5 5193.4 
HD1 i8O GGTTGGTOGTGGTTGG  76 89 5190.7 5194.0 
HD1 i9O GGTTGGTGOTGGTTGG  75 91 5193.2 5194.0 
HD1-22 r8P GGTTGGTPTGGTTGGAAAAAAAAAAAAAAA
AGTCCGTGGTAGGGCAGGTTGGGGTGACT  
86 93 a) 18710.0 
HD1-22 r7O GGTTGGOGTGGTTGGAAAAAAAAAAAAAA
AAGTCCGTGGTAGGGCAGGTTGGGGTGACT  
78 86 a) 18735.6 
HD1-22 r8Y GGTTGGTYTGGTTGGAAAAAAAAAAAAAA
AAGTCCGTGGTAGGGCAGGTTGGGGTGACT  
90 98 a) 18701.6 
a)MALDI-TOF analysis on a Ultraflex II TOF/TOF system from Bruker not possible. 
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Supporting Figure 1: a) Dissociation constants, b) thrombin time and c) activated partial 
thromboplastine time (aPTT) of PAH-aptamer insertion variants in relation to HD1. HD1 T4A: non-
binding single mutation control oligonucleotide. 
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Supporting Figure 2: Concentration dependent anticoagulant activity of selected PAH-modified variants 
as measured by a) and b) thrombin time and c) activated partial thromboplastine time (aPTT). 
 
Supporting figure 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supporting Figure 3: Excerpts of a 250 ms NOESY spectrum of HD1 r8P recorded at 25°C in 9:1 
H2O:D2O (pH = 7, 100 mM K+). Shown is the aromatic‒methyl and H2’/H2’’ region (top two panels) and 
the aromatic‒H1’ region (bottom panel). Assignments are indicated for cross peaks. 
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Supporting Figure 4: The imino‒imino region of a 250 ms NOESY spectrum of HD1 r8P recorded at 
25°C in 9:1 H2O:D2O (pH = 7, 100 mM K+). Four resonances are observed in the typical range for anti 
guanosines and four in the range for syn residues. The imino resonances are not assigned. 
 
 
 
 
